此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

调查 HMB-001 在格兰茨曼血小板无力症中的安全性、耐受性、药代动力学、药效学和疗效的 1/2 期研究

2026年9月24日 更新者:Hemab ApS

一项 1/2 期、首次人体、单次和多次递增剂量研究,旨在调查 HMB-001 在格兰兹曼血小板无力症受试者中的安全性、耐受性、药代动力学、药效学和功效

The goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia.

The main questions it aims to answer are:

  • Parts A, B, and C: To determine the safety and tolerability of HMB-001
  • Part A: To establish the dose level(s) and dosing interval(s) of HMB-001 to be investigated in Parts B and C
  • Parts B and C: To estimate the ability of HMB-001 to prevent the number and severity of bleeds

Part A will assess differing singular doses of HMB-001 in small groups of participants. The dose administered to a newly enrolled participant (or groups of participants) may only increase if analysis of data from previous dosing shows it is safe to do so. The planned duration of participation in Part A is approximately 6 months, which consists of a Screening Period, an optional Run-in Observation Period, and a follow-up period of 8 weeks.

Part B is similar to Part A as it involves testing different dose levels of HMB-001 in small groups of participants. However, in Part B, HMB-001 is given multiple times over a 3-month period, either weekly, every 2 weeks, or every 4 weeks. Part B consists of a Screening Period, a Run-in Observation Period, a 3-month Treatment Period, and a Safety Follow-up following the last dose of HMB-001.

Part C is open to participants from Part B and consists of approximately a 18-month Treatment Period and a Safety Follow-up following the last dose of HMB-001.

研究概览

地位

主动,不招人

干预/治疗

研究类型

介入性

注册 (估计的)

57

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Florence、意大利
        • Azienda Ospedaliero-Universitaria Careggi (Part B/C)
      • Milan、意大利
        • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano (Part B/C)
      • Leuven、比利时
        • University Hospital Leuven - Campus Gasthuisberg (Part B/C)
      • Le Kremlin-Bicêtre、法国
        • AP-HP Hopital Bicetre (Part B/C)
      • Marseille、法国
        • AP-HM - Hopital de la Timone
      • Paris、法国
        • AP-HP Hopital Necker-Enfants Malades (Part B/C)
    • California
      • La Jolla、California、美国、92093
        • University of California, San Diego (UCSD) (Part B/C)
    • Louisiana
      • New Orleans、Louisiana、美国、70112
        • Tulane University Medical Center (Part B/C)
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic - Rochester (Part B/C)
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15213
        • Hemophilia Center of Western Pennsylvania (HCWP) (Part B/C)
    • Washington
      • Seattle、Washington、美国、98101
        • Washington Institute for Coagulation (Part B/C)
      • Birmingham、英国
        • Queen Elizabeth Hospital Birmingham (Part B/C)
      • Leeds、英国
        • Leeds Teaching Hospitals NHS Trust
      • London、英国
        • Richmond Pharmacology Ltd (Part A/B/C)
      • London、英国
        • Royal Free London NHS Foundation Trust (Part B/C)
      • Whitechapel、英国
        • The Royal London Hospital (Part B/C)
      • Utrecht、荷兰
        • Universitair Medisch Centrum Utrecht (Part B/C)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 67年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Part A Inclusion Criteria:

  1. Age 18 to 65 years, at the time of signing informed consent.

  2. Glanzmann thrombasthenia; documented abnormal, diagnostic platelet aggregometry plus deficiency of the αIIbβ3 (GPIIb/GPIIIa) receptor via flow cytometry; or genetic diagnosis.

  3. Has the ability to provide informed consent.

  4. Has an understanding, ability, and willingness to fully comply with trial procedures and restrictions.

  5. Vital signs are within the following ranges at Screening:

    1. Resting heart rate ≤ 105 bpm (after at least 5 minutes of resting).
    2. Blood pressure (BP): Resting BP (after at least 5 minutes of resting or based on 24 hours monitor demonstrating normotensive BP): i. Systolic BP: 90 - 140 mmHg. ii. Diastolic BP: 40 - 90 mmHg.
  6. Women of child-bearing potential (WOCBP) have a negative serum pregnancy test within 72 hours prior to the first dose of study drug.

  7. WOCBP agree to use highly effective contraceptive methods (excluding estrogen-containing combined oral contraceptive pill) as per exclusion criteria and avoid egg donation for 14 days prior to Day 1, during the study treatment, and for 6 months after the last dose of study drug.

  8. Men of child-producing potential agree to use highly effective contraceptive methods and avoid sperm donation for 14 days prior to Day 1, during the study treatment, and for 6 months after the last dose of study drug.

  9. Participants must meet the following baseline organ function, indicated by laboratory criteria:

    1. Evidence of no greater than mild to moderate reduction in renal function (stage 3a kidney disease), measured by an estimated glomerular filtration rate (eGFR) of ≥45 ml/min/1.73m2 at Screening
    2. An aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin ≤ 1.5 x upper limit of normal (ULN) range at Screening. For participants with a history of Gilbert's Syndrome, total bilirubin ≤ 2 × ULN at Screening
    3. Hemoglobin >85 g/L and platelet count >120 x 10^9/L at Screening.

Part B Inclusion Criteria:

  1. Has the ability to provide informed consent, and has an understanding, ability, and willingness to fully comply with clinical trial procedures and restrictions.

  2. Age 18 to 65 years.

  3. Glanzmann thrombasthenia; Genetic diagnosis is required. Abnormal, diagnostic platelet aggregometry plus deficiency of the αIIbβ3 (GPIIb/GPIIIa) receptor via flow cytometry should be recorded if available.

  4. Patients should experience bleeding symptoms associated with Glanzmann Thrombasthenia defined as approximately two bleeding events per week of any severity and any type and at least one spontaneous or traumatic bleed that requires a prescribed treatment, medical or surgical procedure within the last 12 months.

  5. Vital signs are within the following ranges at Screening:

    1. Resting heart rate ≤105 bpm (after at least 5 minutes of resting)
    2. BP: Resting BP (after at least 5 minutes of resting or based on 24 hours monitor demonstrating normotensive BP): i. Systolic BP: 90 - 140 mmHg; ii. Diastolic BP: 40 - 90 mmHg.
  6. Women of child-bearing potential (WOCBP) have a negative serum pregnancy test within 72 hours prior to the first dose of study drug.

  7. WOCBP agree to use a highly effective contraceptive method and to avoid egg donation for 14 days prior to Day 1, during the study treatment, and for 6 months after the last dose of study drug. If utilizing an oral contraceptive, women must be on a stable dose of a non-estrogen-containing formulation for at least 8 weeks prior to the start of the Run-in Observation Period and for 8 weeks after the last dose of study drug.

  8. Men of child-producing potential agree to use highly effective contraceptive methods and avoid sperm donation for 14 days prior to Day 1, during the study treatment, and for 6 months after the last dose of study drug.

  9. Participants must meet the following baseline organ function, indicated by laboratory criteria:

    1. Evidence of no greater than mild to moderate reduction in renal function (stage 3a kidney disease), measured by an eGFR of ≥45 ml/min/1.73m2 at Screening.
    2. An AST, ALT, and total bilirubin ≤1.5 ULN range at Screening. For participants with a history of Gilbert's Syndrome, total bilirubin ≤2 × ULN at Screening.
    3. Hemoglobin >85 g/L and platelet count >120 x 10^9/L at Screening.

Part A Exclusion Criteria

  1. Severe infection or inflammation at the time of Screening.
  2. History of clinically significant hypersensitivity associated with monoclonal antibody therapies.
  3. Personal history of venous or arterial thrombosis or thromboembolic disease, with the exception of catheter-associated, superficial vein thrombosis.
  4. Known severe congenital or acquired thrombophilia.
  5. Has a positive test for Hepatitis B surface antigen (HbsAg), Hepatitis C antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at Screening with RNA level above the lower limit of detection. Participants with a positive test for HCV Ab may be included if they have a negative RNA test, consistent with cleared infection. Participants with an HIV RNA level lower than the limit of detection may be included.
  6. Other conditions that substantially increase risk of thrombosis by the discretion of the investigator including, but not limited to: significant family history, body mass index (BMI) >30 kg/m2 (moderately obese, adjusted for ethnicity), reduced mobility, active malignancy, major surgery within 6 weeks preceding first dose of study drug, post-partum within 12 weeks preceding first dose of study drug.
  7. Women who are using estrogen-containing medication or hormone modulators (within 8 weeks pre-dose to 8 weeks post-dose of study drug).
  8. Clinically significant cardiovascular disease.
  9. Other conditions that substantially increase the risk of cardiovascular events by the discretion of the Investigator including, but not limited to: smoking, cocaine use, and uncontrolled hypertension.
  10. Congenital or acquired bleeding disorders other than Glanzmann thrombasthenia.
  11. Concurrent disease, treatment, medication, or abnormality in clinical laboratory tests that may pose additional risk.
  12. Addiction or other diseases that prevent the participant from appropriately assessing the nature and scope of the clinical study or participating in study procedures.
  13. Received any live vaccine within 4 weeks of enrollment or is planning to have a live vaccine during the study period.
  14. Received investigational medication in another clinical study within 5 half-lives before administration of study drug.
  15. Female participants who are pregnant or breastfeeding.

Part B Exclusion Criteria

  1. Active severe infection or inflammation at the time of Screening or prior to the first dose of study drug.

  2. History of clinically significant hypersensitivity associated with monoclonal antibody therapies.

  3. Personal history of venous or arterial thrombosis or thromboembolic disease, with the exception of catheter-associated, superficial vein thrombosis.

  4. Co-existing thrombophilic disorder, as determined by the presence of any of the below (or via historical results, where available):

    • Homozygous for Factor V Leiden gene mutation
    • Compound heterozygous for Factor V Leiden gene mutation
    • Prothrombin G20210A mutation
    • Antithrombin III, Protein C deficiency or Protein S deficiency with activity levels of ≤50% in participants with at least 1 second-degree relative with an unprovoked venous thromboembolism (VTE), or a first-degree relative with a minimally provoked VTE or at Investigator discretion for participants with an unknown family history
  5. Family history of unprovoked venous thrombosis in first degree relative.

  6. Has a positive test for HbsAg, HCV Ab, or HIV Ab at Screening with RNA level above the lower limit of detection. Participants with a positive test for HCV Ab may be included if they have a negative RNA test, consistent with cleared infection. Participants with an HIV RNA level lower than the limit of detection may be included.

  7. Other conditions that substantially increase risk of thrombosis by the discretion of the investigator including, but not limited to: BMI >30 kg/m2 (moderately obese, adjusted for ethnicity), reduced mobility, active malignancy major surgery within 6 weeks preceding first dose of study drug, post-partum within 12 weeks preceding first dose of study drug.

  8. Women who are using estrogen-containing medication or hormone modulators from 8 weeks prior to the first dose of study drug until 8 weeks after the last dose of study drug (see separate inclusion criterion for non-estrogen containing contraception requirement).

  9. Clinically significant cardiovascular disease.

  10. Other conditions that substantially increase risk of cardiovascular events by the discretion of the Investigator including, but not limited to: smoking tobacco products, cocaine use, uncontrolled hypertension and untreated hyperlipidemia.

  11. Congenital or acquired bleeding disorders other than Glanzmann thrombasthenia.

  12. Concurrent disease, treatment, medication, or abnormality in clinical laboratory tests that may pose additional risk.

  13. Addiction or other diseases that prevent the participant from appropriately assessing the nature and scope of the clinical study or participating in study procedures.

  14. Received any live vaccine within 4 weeks of enrollment or is planning to have a live vaccine during the study period.

  15. Received investigational medication in another clinical study within 5 half-lives before administration of study drug.

  16. Female participants who are pregnant (including a positive serum pregnancy test at Screening) or breastfeeding.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Single or Multiple ascending dose of HMB-001

Open-label, single or multiple ascending dose of HMB-001

HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
A 部分:通过体检、生命体征、临床实验室评估和心电图参数的变化评估安全性
大体时间:从基线到第 57 天
从基线到第 57 天
B 部分:根据治疗中出现的 AE 发生率评估安全性
大体时间:从基线到第 106 天/提前终止 (ET)/研究结束 (EOS)
从基线到第 106 天/提前终止 (ET)/研究结束 (EOS)
B 部分:通过体检、生命体征、临床实验室评估和心电图参数的变化评估安全性
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B 部分:通过出血频率评估 HMB-001 的初步预防效果:年化出血率 (ABR)
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
A 部分:通过治疗中出现的不良事件 (TEAE) 的发生率评估安全性
大体时间:从基线到第 57 天
从基线到第 57 天
B 部分:通过出血频率评估 HMB-001 的初步预防效果:年化治疗出血率 (ATBR)
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
Part C: 通过治疗中出现的不良事件发生率评估安全性
大体时间:第99天至第687天/提前终止(ET)/研究结束(EOS)
第99天至第687天/提前终止(ET)/研究结束(EOS)
C部分:通过体格检查、生命体征、临床实验室评估和心电图参数的变化评估安全性
大体时间:第 99 天至第 687 天/提前终止 (ET)/研究结束 (EOS)
第 99 天至第 687 天/提前终止 (ET)/研究结束 (EOS)
Part C:通过出血频率评估 HMB-001 的初步预防效果:年度治疗出血率(ATBR)和年度化出血率(ABR)
大体时间:第 99 天至第 687 天/提前终止 (ET)/研究结束 (EOS)
第 99 天至第 687 天/提前终止 (ET)/研究结束 (EOS)

次要结果测量

结果测量
大体时间
A 部分:HMB-001 的血浆浓度
大体时间:从基线到第 57 天
从基线到第 57 天
A 部分:药代动力学 (PK) 参数:观察到的最大血浆浓度 (Cmax)
大体时间:从基线到第 57 天
从基线到第 57 天
A 部分:PK 参数:从零时间到最后可定量浓度的曲线下面积 (AUClast)
大体时间:从基线到第 57 天
从基线到第 57 天
A 部分:PK 参数:从零时间到外推无限时间的曲线下面积 (AUCinf)
大体时间:从基线到第 57 天
从基线到第 57 天
A 部分:PK 参数:达到最大观察血浆浓度的时间 (Tmax)
大体时间:从基线到第 57 天
从基线到第 57 天
A 部分:抗药物抗体 (ADA) 形成
大体时间:从基线到第 57 天
从基线到第 57 天
B 部分:HMB-001 的血浆浓度
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B 部分:PK 参数:Cmax
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B 部分:PK 参数:AUClast
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B 部分:PK 参数:AUCinf
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B 部分:PK 参数:Tmax
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B 部分:通过出血严重程度(严重出血事件的发生)评估 HMB-001 的初步预防效果
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B部分:通过输血产品使用量评估HMB-001的初步预防效果
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B 部分:通过 FVIIa 使用量评估 HMB-001 的初步预防效果
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B 部分:通过红细胞 (RBC) 输注量评估 HMB-001 的初步预防效果
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B 部分:通过铁状态评估 HMB-001 的初步预防效果:血红蛋白相对于基线的平均变化
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B 部分:通过铁状态评估 HMB-001 的初步预防效果:铁蛋白和总铁相对于基线的平均变化
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B 部分:ADA 形成
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
A 部分:PD 参数:凝血因子 VII (FVII) 相对于基线的最大、平均增加
大体时间:从基线到第 57 天
从基线到第 57 天
A 部分:PD 参数:凝血酶原时间 (PT) 相对于基线的最大、平均减少量
大体时间:从基线到第 57 天
从基线到第 57 天
A 部分:PD 参数:活化部分凝血活酶时间 (aPTT) 相对于基线的最大、平均减少量
大体时间:从基线到第 57 天
从基线到第 57 天
B 部分:根据 ABR 子类别评估的 HMB-001 的初步预防效果,包括但不限于自发性和影响性
大体时间:从基线到第 106 天/ET/EOS
从基线到第 106 天/ET/EOS
B部分:EuroQol五维五水平量表(EQ-5D-5L)评分相对于基线的变化
大体时间:从基线至第85天/治疗结束(EOT)
从基线至第85天/治疗结束(EOT)
B部分:患者报告结局测量信息系统(PROMIS)-29评分相对于基线的变化
大体时间:从基线到第85天/治疗结束(EOT)
从基线到第85天/治疗结束(EOT)
B部分:工作生产力和活动障碍(WPAI)评分相对于基线的变化
大体时间:从基线至第85天/治疗结束(EOT)
从基线至第85天/治疗结束(EOT)
C部分:HMB-001的血浆浓度
大体时间:第99天至第687天/提前终止(ET)/研究结束(EOS)
第99天至第687天/提前终止(ET)/研究结束(EOS)
C部分:PK参数:Cmax
大体时间:第99天至第687天/提前终止 (ET)/研究结束 (EOS)
第99天至第687天/提前终止 (ET)/研究结束 (EOS)
C部分:药代动力学参数:AUClast
大体时间:第99天至第687天/提前终止(ET)/研究结束(EOS)
第99天至第687天/提前终止(ET)/研究结束(EOS)
Part C:PK参数:AUCinf
大体时间:第99天至第687天/早期终止 (ET)/研究结束 (EOS)
第99天至第687天/早期终止 (ET)/研究结束 (EOS)
C部分:药代动力学参数:Tmax
大体时间:第99天至第687天/早期终止(ET)/研究结束(EOS)
第99天至第687天/早期终止(ET)/研究结束(EOS)
C部分:通过出血事件评估的HMB-001初步预防效果
大体时间:第99天至第687天/提前终止(ET)/研究结束(EOS)
第99天至第687天/提前终止(ET)/研究结束(EOS)
C部分:通过出血严重程度(严重出血事件的发生情况)评估HMB-001的初步预防效果
大体时间:第99天至第687天/提前终止(ET)/研究结束(EOS)
第99天至第687天/提前终止(ET)/研究结束(EOS)
Part C:根据输血产品使用量评估的 HMB-001 初步预防效果
大体时间:第99天至第687天/早期终止(ET)/研究结束(EOS)
第99天至第687天/早期终止(ET)/研究结束(EOS)
C部分:通过FVIIa使用量评估HMB-001的初步预防效果
大体时间:第99天至第687天/提前终止(ET)/研究结束(EOS)
第99天至第687天/提前终止(ET)/研究结束(EOS)
C部分:通过红细胞(RBC)输注量评估的HMB-001初步预防效果
大体时间:第99天至第687天/提前终止/研究结束
第99天至第687天/提前终止/研究结束
C部分:通过铁状态评估的HMB-001初步预防效果:血红蛋白相对基线的平均变化
大体时间:第99天至第687天/提前终止(ET)/研究结束(EOS)
第99天至第687天/提前终止(ET)/研究结束(EOS)
C部分:通过铁状态评估HMB-001的初步预防效果:铁蛋白和总铁相对于基线的平均变化
大体时间:第99天至第687天/早期终止(ET)/研究结束(EOS)
第99天至第687天/早期终止(ET)/研究结束(EOS)
Part C:ADA 形成
大体时间:从基线至第673天/治疗结束(EOT)
从基线至第673天/治疗结束(EOT)
C部分:欧洲五维健康量表5级版(EQ-5D-5L)评分相对于基线的变化
大体时间:从基线至第673天/治疗结束(EOT)
从基线至第673天/治疗结束(EOT)
C部分:患者报告结局测量信息系统(PROMIS)-29评分相对于基线的变化
大体时间:从基线至第673天/治疗结束(EOT)
从基线至第673天/治疗结束(EOT)
C部分:工作生产力和活动障碍(WPAI)评分相对于基线的变化
大体时间:从基线至第673天/治疗结束(EOT)
从基线至第673天/治疗结束(EOT)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2022年12月13日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2027年8月1日

研究注册日期

首次提交

2024年1月9日

首先提交符合 QC 标准的

2024年1月9日

首次发布 (实际的)

2024年1月18日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅